Study of vascular risk in Navarre: Objectives and design. Prevalence of metabolic syndrome and of vascular risk factors;Estudio de riesgo vascular en Navarra: Objetivos y diseño. Prevalencia del síndrome metabólico y de los factores mayores de riesgo vascular

Anales del Sistema Sanitario de Navarra

Volumn 30, Issue 1, 2007, Pages 113-124

  Viñes, José Javier ^a,g   Diez J ^b   Guembe, M J ^a   Gonzalez P ^a   Amezqueta C ^c   Barba, J ^d   Sobejano, I ^a   Martinez Vila E ^d   Grijalba, A M ^e   Serrano, M ^c   Moreno, C ^f   Los Arcos, E ^e   Guerrero, D ^b  

^a Unidad de Evaluación   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Unidad de Patología Crónica Compleja Servicio de Pediatría y Áreas Específicas Hospital Universitario de Navarra Servicio Navarro de Salud Osasunbidea   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e Universidad Pública de Navarra   (Spain)

^f INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^g Investigacion y Desarrollo Sanitarios   (Spain)

Author keywords

Navarra (Espa a); Prevalence metabolic syndrome; Risk vascular factors; Sub clinical lesions

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GEOGRAPHY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE;

ADOLESCENT; ADULT; CATCHMENT AREA (HEALTH); CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SPAIN; VASCULAR DISEASES;

EID: 34248361533     PISSN: 11376627     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. INE base Defunciones según causa de muerte. Disponible en: http://www.ine.es/inebase/cgi/um?M=%2Ft15%2Fp417&O=inebase&N=&L=0 [08/08/2006}.
2. Mortalidad por cáncer y otras causas en España, 2002.Centro Nacional de Epidemiología. Área de Epidemiología Ambiental y Cáncer. [Citado 18 junio de 2005]. Disponible : http://cne.isciii.es/ cancer/mort2002.txt.
3. Mortalidad provincial por enfermedad cerebro vascular y por cardiopatía isquémica por sexo. Disponible en: www.isciii.es/htdocs/centros/epidemiologia/epi_cerebro_tabla4.jsp [08/08/2006].
4. Standard Death Rate, Diseases of the circulatory system, per 100000 . http://data.euro.who.int [08/08/2006].
5. GUEMBE MJ. Prevalencia por 100 de factores de riesgo vascular en Navarra 1993: Bol Salud Pub Nav 1994; 7: 2-8.
6. SATTAR N, GAW A, SCHERBAKOVA O, FORD I, O'REILLY D, HAFFNER SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2003; 108: 414-419.
7. RIDKER P, BURING JE, COOK NR, RIFAI N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14719 Initially Healthy American Women. Circulation 2003; 107: 391-397.
8. Grupo de Trabajo Resistencia a la insulina de la Sociedad Española de Diabetes tipo 2. Resistencia a la insulina y su implicación en múltiples factores de riesgo asociados a diabetes tipo 2. Med Clin (Barc) 2002; 119: 458-463.
9. FORD ES, GILES WH, DIETZ WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
10. CAMERON AJ, SHAW JE, ZIMMET PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin N Am 2004; 33: 351-375.
11. MARQUES-VIDAL P, MAZOYER E, BONGARD V, GOURDY P, RUIDAVETS JB, DROUET L et al. Prevalence of insulin resistanse syndrome in southwestern France and its relationship with inflamatory and hemostatic markers. Diabetes Care 2002; 25: 1371-1377.
12. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation, and Treatment of high blood Cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2509.
13. GRUNDY SM, CLEEMAN JI, DANIELS SR, DONATO KA, ECKEL RH, FRANKLIN BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
14. ÁLVAREZ EE, RIBAS L, SERRA L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin (Barc) 2003; 120: 172-174.
15. Registro de infarto agudo de miocardio de Navarra, 2003. Memoria Servicio Navarro de salud. Pamplona: Gobierno de Navarra, 2004.
16. LAKKA HM, LAAKSONEN DE, LAKKA TA, NISKANEN LK, KUMPUSALO E, TUOMILENTO V. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 1709-2716.
17. GIMENO JA, LOU LM, MOLINERO E, BONED, B, PORTILLA DP. Influencia del Síndrome Metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2. Rev Esp Cardiol 2004; 57: 507-513.
18. MCNEILL AM, ROSAMOND WD, GIRMAN CJ, GOLDEN SH, SCHMIDT MI, EAST HE et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390.
19. NINOMIYA JK, L'ITALIEN G, CRIQUI MH, WHYTE JL, GAMST A, CHEN RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004;109: 42-46.
20. ROTHMAN KJ, BOICE JD. Epidemiologic Analysis with a Programmable calculator. NIH Publication no 79-1969-1979.
21. MIETTINEN OS. Individual matching in the case of al or none reponse. Biometrics 1969; 25: 339-354.
22. WILSON PWF, D'AGOSTINO RB, LEVY D, BELANGER AM, SILVERSCHATZ H, KANNEL WB. Prediction of coronary heart disease using risk factor categries. Circulation 1998; 97: 1837-1847.
23. CONROY RM, PYORALA K, FITZGERALD AP, SANS S, MENOTTI A, DE BACKER G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
24. MARRUGAT J, SOLANAS P, D'AGOSTINO R, SULLIVAN L, ORDOVAS J, CORDÓN F et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol 2003; 56: 253-261.
25. FORD ES. Prevalence of the Metabolic Syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-2749.
26. BANEGAS JR, VILLAR F, PÉREZ C, JIMÉNEZ R, GIL E, MUÑIZ J. Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a 64 años. Rev San Hig Pub 1993; 67: 419-445.
27. MASIÁ R, PENA A, MARRUGAT J, SALA J, VILA J, PAVESI M et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Community Health 1998; 52: 707-715.
28. MEDRANO MJ, CERRATO E, BOIX R, DELGADO-RODRIGUEZ M. Factores de riesgo vascular en la población española: metaanálisis de estudios transversales. Med Clin 2005; 124: 606-612.
29. WOLF-MAIER K, COOPER RS, BANEGAS JR, GIAMPAOLI S, HENSE HW, JOFFRES M et al. Hypertension prevalence and blood pressure levels in 6 european countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
30. JANSEN I, KATZMARZYK PT, ROSS R. Waist circumference and not mass index explains obesity related health risk. Am J Clin Nutr 2004; 79: 379-384.
31. COWIE C, RUST KF, BYRD-HOLT D, EBERHARDT MS, FLEGAL KM, ENGELGAU MM et al. Prevalence of Diabetes and impaired fasting glucose in adults in the U.S. population. National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-1268.
32. FORD ES, GILES WH, MOKDAD AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444-2449.